Rhino-Conjunctivitis – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Rhino-Conjunctivitis – Pipeline Review, H2 2019’, provides an overview of the Rhino-Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis

– The report reviews pipeline therapeutics for Rhino-Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Rhino-Conjunctivitis therapeutics and enlists all their major and minor projects

– The report assesses Rhino-Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Rhino-Conjunctivitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALK-Abello AS

Allergy Therapeutics Plc

ASIT Biotech SA

Faes Farma SA

HAL Allergy BV

Iltoo Pharma

Inmunotek SL

Laboratorios LETI SL

Roxall Medizin GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rhino-Conjunctivitis Overview

Rhino-Conjunctivitis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rhino-Conjunctivitis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rhino-Conjunctivitis Companies Involved in Therapeutics Development

ALK-Abello AS

Allergopharma GmbH & Co KG

Allergy Therapeutics Plc

ASIT Biotech SA

Astellas Pharma Inc

Bial - Portela & Ca SA

Faes Farma SA

HAL Allergy BV

Laboratorios LETI SL

Oxagen Ltd

Rhino-Conjunctivitis Drug Profiles

Acaroid Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis and Rhino conjunctivitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Birch Pollen Allergy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhino conjunctivitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhino conjunctivitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for House Dust Mite Induced Allergic Rhinitis and Rhino conjunctivitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhino conjunctivitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhino conjunctivitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergovac Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-4070 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bilastine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-41 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gp-ASIT Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hdm-ASIT Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Birch Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Grass Drug Profile

Product Description

Mechanism Of Action

R&D Progress

short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Timapiprant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rhino-Conjunctivitis Dormant Projects

Rhino-Conjunctivitis Discontinued Products

Rhino-Conjunctivitis Product Development Milestones

Featured News & Press Releases

Feb 12, 2018: Completion of recruitment in PQ Grass Phase II trial

Jan 09, 2018: Allergy Therapeutics: PQ Birch Phase III clinical trial completes recruitment

Oct 19, 2017: Allergy Therapeutics: Commencement of dosing in PQ Grass Phase II Trial

May 30, 2017: ASIT biotech to disclose the detailed results of its phase III clinical study with gp-ASIT+ at EAACI 2017

Nov 30, 2015: Allergy Therapeutics Completes Patient Enrolment For Birch Study

May 18, 2014: BioTech Tools will be present at the EAACI congress

Jan 24, 2014: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet

Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultra short Grass Allergy Vaccine by Allergy Therapeutics

Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites

Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil

Nov 28, 2011: Allergy Therapeutics Submits Complete Response to PEI In Germany And Clinical Study Protocol To FDA

Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study

Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain

Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries

Dec 02, 2010: Faes Farma: Bilastine is approved in eight European countries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Rhino-Conjunctivitis, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Rhino-Conjunctivitis – Pipeline by ALK-Abello AS, H2 2019

Rhino-Conjunctivitis – Pipeline by Allergy Therapeutics Plc, H2 2019

Rhino-Conjunctivitis – Pipeline by ASIT Biotech SA, H2 2019

Rhino-Conjunctivitis – Pipeline by Faes Farma SA, H2 2019

Rhino-Conjunctivitis – Pipeline by HAL Allergy BV, H2 2019

Rhino-Conjunctivitis – Pipeline by Iltoo Pharma, H2 2019

Rhino-Conjunctivitis – Pipeline by Inmunotek SL, H2 2019

Rhino-Conjunctivitis – Pipeline by Laboratorios LETI SL, H2 2019

Rhino-Conjunctivitis – Pipeline by Roxall Medizin GmbH, H2 2019

Rhino-Conjunctivitis – Dormant Projects, H2 2019

Rhino-Conjunctivitis – Dormant Projects, H2 2019 (Contd..1), H2 2019

Rhino-Conjunctivitis – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Rhino-Conjunctivitis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports